LGBTQ equality
A (97)
Screens
Advertising
No
Alcohol
No
Animal treatment
Yes
Animal treatment
Yes
Anti-abortion support
Yes
Cannabis
No
Carbon emissions intensity
No
Coal
No
Contraceptives
Yes
Deforestation - financing
No
Deforestation - supply chain
No
Discrimination controversies
No
Environmental controversies
No
Factory farming
No
Fast food
No
Firearms
No
For-profit health care
No
Fossil fuel
No
Fur
No
Gambling
No
Genetic engineering
No
Health-related controversies
No
Human rights controversies
No
Human trafficking
No
Interest-based products
No
Interest-bearing debt
No
Interest-bearing securities
No
Iran
Yes
Military contracting
Yes
Misleading communication
No
Music
No
Myanmar
No
Northern Ireland (Macbride)
No
North Korea
No
No SBTI commitment
Yes
Nuclear
No
Oil and gas
No
Opioid controversies
No
Oppressive governments
No
Pharma controversies
Yes
Pork
No
Pornography
No
Predatory lending
No
Prison involvement
No
Privacy breaches
No
Pro-life
No
Russia
Yes
Single-use plastic
No
Stem cell research
Yes
Sudan
No
Sugar
No
Syria
No
Tobacco
No
Undermining US elections
No
Weapons
No
Impact

Cause LLY
Peer rank
LGBTQ equality

Name Rating
Loading...
Screens
Advertising
No
Alcohol
No
Animal treatment
Yes
Animal treatment
Yes
Anti-abortion support
Yes
Cannabis
No
Carbon emissions intensity
No
Coal
No
Contraceptives
Yes
Deforestation - financing
No
Deforestation - supply chain
No
Discrimination controversies
No
Environmental controversies
No
Factory farming
No
Fast food
No
Firearms
No
For-profit health care
No
Fossil fuel
No
Fur
No
Gambling
No
Genetic engineering
No
Health-related controversies
No
Human rights controversies
No
Human trafficking
No
Interest-based products
No
Interest-bearing debt
No
Interest-bearing securities
No
Iran
Yes
Military contracting
Yes
Misleading communication
No
Music
No
Myanmar
No
Northern Ireland (Macbride)
No
North Korea
No
No SBTI commitment
Yes
Nuclear
No
Oil and gas
No
Opioid controversies
No
Oppressive governments
No
Pharma controversies
Yes
Pork
No
Pornography
No
Predatory lending
No
Prison involvement
No
Privacy breaches
No
Pro-life
No
Russia
Yes
Single-use plastic
No
Stem cell research
Yes
Sudan
No
Sugar
No
Syria
No
Tobacco
No
Undermining US elections
No
Weapons
No
Top metrics
Sample of top metrics driving Eli Lilly's rating for LGBTQ equality (A, relative to other companies). Hover or click on a bubble for more info. See details for all metrics in table below
Loading...
All metrics
Metrics used to rate Eli Lilly for LGBTQ equality. Click on a metric for more info
Metric Source Data Normalized
Loading...

Data status

Summary statistics on data used to rate Eli Lilly for LGBTQ equality

...

of potential metrics used

...

unique data

...

peer-average data

5 days ago

last updated

...

company filings data

...

government data

...

Ethos research

...

independent organization data
Controversies
Controversies associated with Eli Lilly. Click on a controversy for more info
Title Date Severity
Loading...
* Indicates data is an average of peer group, or industry if peer data not available. Used when data for company not available.
Normalized scores are relative to other companies. Learn more about our ratings methodology
Note that all controversies information is based on publicly-available information.
LLY Price
$323.00
Last available end-of-day price. Full disclosure
Revenue
$28.32 billion
Market cap
$225.51 billion
Public/private
Public
Hypothetical growth of $10,000
Historical performance
Company
Founded
1876
Employees
35,000
Sector
Healthcare
Industry
Pharmaceuticals & Biotech
Peer group
Drug Manufacturers - Major
Headquarters
In, United States
Share classes
LLY
Mission
We pursue pharmaceutical innovation, provide high-quality products, and strive to deliver superior business results. We continually search for new ways to improve everything we do.
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Material causes
Ethos considers the following causes material for Eli Lilly, based on its industry peer group Drug Manufacturers - Major. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.